Publications by authors named "Jeffery Russell"

Claim this Profile
A
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
Brett G M Hughes, Alexander Guminski, Samantha Bowyer, Michael R Migden, Chrysalyne D Schmults, Jeffery S Russell

J Am Acad Dermatol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Management of Advanced Adrenocortical Carcinoma.
Jeffery S Russell

Curr Treat Options Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Dose Escalation of Stereotactic Body Radiation Therapy and Concurrent Cisplatin for Reirradiation of Unresectable, Recurrent Squamous Cell Carcinoma of the Head and Neck.
Michelle I Echevarria, George Q Yang, Dung-Tsa Chen, Kedar Kirtane, Jeffery Russell

Int J Radiat Oncol Biol Phys· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.
Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Raluca Verona, Diego Vieyra, Jeffery Russell

Blood Adv· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
Ajai Chari, Monique C Minnema, Jesus G Berdeja, Albert Oriol, Niels W C J van de Donk, Jeffery Russell

N Engl J Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Sungjune Kim, Evan Wuthrick, Dukagjin Blakaj, Zeynep Eroglu, Claire Verschraegen, Jeffery Russell

Lancet· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Behavioral Physical Activity Intervention to Manage Moderate and Severe Fatigue Among Head and Neck Cancer Patients-Pre-efficacy Study in the National Institutes of Health ORBIT Model.
Hsiao-Lan Wang, Susan C McMillan, Nisha Vijayakumar, Sally McDonald, Li-Ting Huang, Jeffery Russell

Cancer Nurs· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Todd C Knepper, Meagan Montesion, Jeffery S Russell, Ethan S Sokol, Garrett M Frampton

Clin Cancer Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Robert L Ferris, Lisa Licitra, Jerome Fayette, Caroline Even, George Blumenschein, Jeffery Russell

Clin Cancer Res· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.
Lise Boussemart, Adrienne Johnson, Alexa B Schrock, Sumanta K Pal, Garrett M Frampton, Jeffery Russell

J Am Acad Dermatol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient choice for high-volume center radiation impacts head and neck cancer outcome.
Arash O Naghavi, Michelle I Echevarria, Tobin J Strom, Yazan A Abuodeh, Puja S Venkat, Jeffery S Russell

Cancer Med· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
Sandra P D'Angelo, Jeffery Russell, Céleste Lebbé, Bartosz Chmielowski, Thilo Gambichler

JAMA Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.
John G D Cannon, Jeffery S Russell, Jinah Kim, Anne Lynn S Chang

JAAD Case Rep· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.
Howard L Kaufman, Jeffery S Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden

J Immunother Cancer· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exergame Grading Scheme: Concept Development and Preliminary Psychometric Evaluations in Cancer Survivors.
Hsiao-Lan Wang, Chiung-Ju Liu, Marcus Kilpatrick, Heather Jim, Susan McMillan, Jeffery Russell

Rehabil Res Pract· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options.
Laurie M Gay, Sungeun Kim, Kyle Fedorchak, Madappa Kundranda, Yazmin Odia, Jeffery Russell

Oncologist· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma.
Todd C Knepper, Morganna L Freeman, Geoffrey T Gibney, Howard L McLeod, Jeffery S Russell

JAMA Dermatol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck.
Tobin Strom, Arash O Naghavi, Jane L Messina, Sungjune Kim, Javier F Torres-Roca, Jeffery Russell

Head Neck· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years.
Tobin J Strom, Arash O Naghavi, Andy M Trotti, Jeffery Russell, Julie A Kish

J Geriatr Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.
Kai Wang, Jeffery S Russell, Jessica D McDermott, Julia A Elvin, Depinder Khaira

Clin Cancer Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nursing Management of Advanced Merkel Cell Carcinoma.
Pamela A Lowry, Morganna L Freeman, Jeffery S Russell

Oncol Nurs Forum· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma.
Tobin Strom, Michael Carr, Jonathan S Zager, Arash Naghavi, Franz O Smith, Jeffery Russell

Ann Surg Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Howard L Kaufman, Jeffery Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden

Lancet Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypermetabolism on (18)F-Fluorodeoxyglucose Positron Emission Tomography Scan Does Not Influence the Interpretation of Thyroid Cytopathology, and Nodules with a SUVmax <2.5 Are Not at Increased Risk for Malignancy.
Pablo Valderrabano, Jaime Montilla-Soler, Mathew Mifsud, Marino Leon, Barbara Centeno, Jeffery Russell

Thyroid· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests.
Pablo Valderrabano, Marino E Leon, Barbara A Centeno, Kristen J Otto, Laila Khazai, Jeffery S Russell

Eur J Endocrinol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis